EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy
GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, for use in adults aged 18 years and above.
With the EMA accepting the application for review, a final decision from the regulatory body in Europe is expected in the first half of 2026.
Arexvy is currently approved for the prevention of lower respiratory tract disease ('LRTD') caused by RSV in all individuals aged 60 years and above, as well as for high-risk individuals aged 50-59 years.
GSK is currently seeking approval for the expanded use of Arexvy in adults aged 18 years and above in the United States and Japan.
Year to date, shares of GSK have risen 20.8% against the industry 's decline of 0.6%.
GSK's Arexvy Sales Remain Lukewarm
Arexvy was the first RSV vaccine for older adults to be approved anywhere in the world.
However, sales of the vaccine have been lukewarm, mainly due to the revised recommendations for RSV vaccinations issued by the Advisory Committee on Immunization Practices ('ACIP') in June 2024.
In June, the ACIP recommended the use of Arexvy for all adults aged 75 years and above. However, for adults aged 60-74 years, the ACIP recommended the vaccine only for those who are at increased risk of severe RSV disease.
Arexvy generated sales worth £78 million in the first quarter of 2025, down 57% year over year due to lower demand in the United States.
Other RSV Vaccine Makers in the Market
Pfizer 's PFE Abrysvo is approved for the prevention of RSV-associated LRTD in all individuals aged 60 years and above, as well as in infants, through maternal immunization.
PFE's Abrysvo is also approved for use in high-risk adults aged 18-59 years in the United States and Europe.
Earlier this year, the ACIP recommended the expanded use of Arexvy and Abrysvo for use in adults aged 50-59 years who are at high risk for severe RSV disease. The updated ACIP recommendation lowers the recommended age for RSV vaccination from 60 years to 50 years for high-risk adults.
The ACIP's recommendation is pending final approval by the director of the U.S. Centers for Disease Control and Prevention ('CDC') and the Department of Health and Human Services.
Moderna 's MRNA RSV vaccine, mResvia, was approved last year by the FDA and the European Commission to prevent RSV-LRTD in older adults aged 60 years and above.
Last week, the FDA approved MRNA's mResvia for use in high-risk adults aged 18-59 years. Moderna is also working on expanding the vaccine's use in pediatric populations.
We note that RSV vaccine sales have been weak across the industry for the 2024-2025 vaccination season due to the restrictive recommendation issued by the U.S. CDC last year for individuals in the 60-74 age bracket.
mResvia generated sales worth $2 million during the first quarter of 2025, while sales of Pfizer's RSV vaccine, Abrysvo, fell 9% year over year to $131 million.
GSK's Zacks Rank
GSK currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Moderna, Inc. (MRNA): Free Stock Analysis Report
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Breaking the Silence: Addressing the Emotional Impact of Hair Loss in Women
London, UK - June 16, 2025 - Hair loss in women is a topic often shrouded in silence, yet it profoundly affects self-esteem and emotional well-being. A recent article by Steph from Renovation Bay-Bee, titled"How Hair Loss Affects Confidence in Women and What You Can Do About It", sheds light on this sensitive issue, offering personal insights and practical advice. Steph candidly discusses her experience with hair thinning, highlighting the emotional toll it takes: "I felt like I was losing a part of myself. My hair was always something I took pride in, and watching it thin was heartbreaking." Her narrative resonates with many women who face similar challenges, emphasizing that hair loss is not merely a cosmetic concern but a deeply personal struggle. Understanding the Causes Hair loss in women can result from various factors, including hormonal changes, stress, nutritional deficiencies, and medical conditions. Steph's article underscores the importance of identifying the root cause to address the issue effectively. Taking Action Steph offers several strategies for managing hair loss: Consult Healthcare Professionals: Seeking medical advice to determine underlying causes. Nutritional Support: Ensuring a balanced diet rich in essential vitamins and minerals. Stress Management: Incorporating relaxation techniques to mitigate stress-related hair loss. Hairstyling Alternatives: Exploring wigs, hairpieces, or new hairstyles to boost confidence. A Call for Empathy and Support Hair loss in women is a multifaceted issue that intertwines physical health and emotional well-being. Steph's article serves as a reminder of the importance of empathy, understanding, and proactive care. Media Contact Company Name: Treatment Rooms London Contact Person: Leigh-Ann Hewer Email: Send Email Address: Putney, Unit 13 Princeton Court, Felsham Road City: London, SW15 1AZ Country: United Kingdom Website:
Winnipeg Free Press
2 hours ago
- Winnipeg Free Press
Dismissed members of CDC vaccine committee call Kennedy's actions ‘destabilizing'
NEW YORK (AP) — All 17 experts recently dismissed from a government vaccine advisory panel published an essay Monday decrying 'destabilizing decisions' made by U.S. Health Secretary Robert F. Kennedy Jr. that could lead to more preventable disease spread. Kennedy last week announced he would 'retire' the entire panel that guides U.S. vaccine policy. He also quietly removed Dr. Melinda Wharton — the veteran Centers for Disease Control and Prevention official who coordinated the committee's meetings. Two days later, he named eight new people to the influential panel. The list included a scientist who criticized COVID-19 vaccines, a leading critic of pandemic-era lockdowns and someone who worked with a group widely considered to be a leading source of vaccine misinformation. 'We are deeply concerned that these destabilizing decisions, made without clear rationale, may roll back the achievements of U.S. immunization policy, impact people's access to lifesaving vaccines, and ultimately put U.S. families at risk of dangerous and preventable illnesses,' the 17 panelists wrote in the Journal of the American Medical Association. The new committee is scheduled to meet next week. The agenda for that meeting has not yet been posted, but a recent federal notice said votes are expected on vaccinations against flu, COVID-19, HPV, RSV and meningococcal bacteria. The removal of Wharton and CDC immunization staff cuts will make it hard for a group of new outside advisers to quickly come up to speed and make fact-based decisions about what vaccines to recommend and not recommend to the public, the experts said. 'The termination of all members and its leadership in a single action undermines the committee's capacity to operate effectively and efficiently, aside from raising questions about competence,' they wrote. A spokeswoman for the U.S. Department of Health and Human Services did not respond to the JAMA commentary, but instead pointed to Kennedy's previous comments on the committee. Kennedy, a leading voice in the anti-vaccine movement before becoming the U.S. government's top health official, has accused the committee of being too closely aligned with vaccine manufacturers and of rubber-stamping vaccines. The Advisory Committee on Immunization Practices, created in 1964, makes recommendations to the CDC director on how vaccines that have been approved by the Food and Drug Administration should be used. CDC directors almost always approve those recommendations, which are widely heeded by doctors and guide vaccination programs. ACIP policies require members to state past collaborations with vaccine companies and to recuse themselves from votes in which they had a conflict of interest, but Kennedy has dismissed those safeguards as weak. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Globe and Mail
5 hours ago
- Globe and Mail
EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy
GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, for use in adults aged 18 years and above. With the EMA accepting the application for review, a final decision from the regulatory body in Europe is expected in the first half of 2026. Arexvy is currently approved for the prevention of lower respiratory tract disease ('LRTD') caused by RSV in all individuals aged 60 years and above, as well as for high-risk individuals aged 50-59 years. GSK is currently seeking approval for the expanded use of Arexvy in adults aged 18 years and above in the United States and Japan. Year to date, shares of GSK have risen 20.8% against the industry 's decline of 0.6%. GSK's Arexvy Sales Remain Lukewarm Arexvy was the first RSV vaccine for older adults to be approved anywhere in the world. However, sales of the vaccine have been lukewarm, mainly due to the revised recommendations for RSV vaccinations issued by the Advisory Committee on Immunization Practices ('ACIP') in June 2024. In June, the ACIP recommended the use of Arexvy for all adults aged 75 years and above. However, for adults aged 60-74 years, the ACIP recommended the vaccine only for those who are at increased risk of severe RSV disease. Arexvy generated sales worth £78 million in the first quarter of 2025, down 57% year over year due to lower demand in the United States. Other RSV Vaccine Makers in the Market Pfizer 's PFE Abrysvo is approved for the prevention of RSV-associated LRTD in all individuals aged 60 years and above, as well as in infants, through maternal immunization. PFE's Abrysvo is also approved for use in high-risk adults aged 18-59 years in the United States and Europe. Earlier this year, the ACIP recommended the expanded use of Arexvy and Abrysvo for use in adults aged 50-59 years who are at high risk for severe RSV disease. The updated ACIP recommendation lowers the recommended age for RSV vaccination from 60 years to 50 years for high-risk adults. The ACIP's recommendation is pending final approval by the director of the U.S. Centers for Disease Control and Prevention ('CDC') and the Department of Health and Human Services. Moderna 's MRNA RSV vaccine, mResvia, was approved last year by the FDA and the European Commission to prevent RSV-LRTD in older adults aged 60 years and above. Last week, the FDA approved MRNA's mResvia for use in high-risk adults aged 18-59 years. Moderna is also working on expanding the vaccine's use in pediatric populations. We note that RSV vaccine sales have been weak across the industry for the 2024-2025 vaccination season due to the restrictive recommendation issued by the U.S. CDC last year for individuals in the 60-74 age bracket. mResvia generated sales worth $2 million during the first quarter of 2025, while sales of Pfizer's RSV vaccine, Abrysvo, fell 9% year over year to $131 million. GSK's Zacks Rank GSK currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Moderna, Inc. (MRNA): Free Stock Analysis Report
